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The cost of asthma medicines
Abstract
Most adults and adolescents with asthma require a preventer inhaler. In Australia these patients are often
prescribed a combination inhaler containing a corticosteroid and a long-acting beta 2 agonist. These
combination inhalers increase the cost of treatment for patients and for government and may not provide
extra benefit. Many patients can control their asthma using an inhaled corticosteroid alone for prevention
of symptoms and flare-ups. Most of the benefits of inhaled corticosteroids are obtained at low doses. To
achieve these benefits it is important to check that the patient is using their inhaler correctly and regularly.
Shared decision making includes discussing the options for treatment. Offering a more affordable
preventer regimen could aid adherence and lead to improved outcomes.
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SUMMARY
Most adults and adolescents with asthma require a preventer inhaler. In Australia these patients
are often prescribed a combination inhaler containing a corticosteroid and a long-acting
beta2 agonist.
These combination inhalers increase the cost of treatment for patients and for government
and may not provide extra benefit. Many patients can control their asthma using an inhaled
corticosteroid alone for prevention of symptoms and flare-ups.
Most of the benefits of inhaled corticosteroids are obtained at low doses. To achieve these
benefits it is important to check that the patient is using their inhaler correctly and regularly.
Shared decision making includes discussing the options for treatment. Offering a more affordable
preventer regimen could aid adherence and lead to improved outcomes.

Introduction
Australian guidelines recommend that most adults
and adolescents with asthma should be taking a
preventer inhaler. This is to minimise symptoms,
prevent a decline in lung function, and to reduce the
risk of exacerbations and asthma-related death.1 For
the majority of patients, most of these benefits can
be achieved with low-dose inhaled corticosteroids
(e.g. beclometasone 200 micrograms/day, budesonide
400 micrograms/day, ciclesonide 160 micrograms/day
or fluticasone propionate 200 micrograms/day).
However, in Australia, most patients are prescribed
inhaled corticosteroids in combination with long-acting
beta2 agonists,2,3 often at moderate or high doses.2
This is common practice, despite these combination
products not being subsidised by the Pharmaceutical
Benefits Scheme (PBS) for the initial treatment
of asthma.
Adherence is higher with combination inhalers
than it is with inhaled corticosteroids alone.
However, Australian data show that less than 20%
of patients are being dispensed enough of either of
these types of preventer inhaler to be taking their
treatment regularly.2

Cost considerations
Out-of-pocket cost is a major factor contributing to
poor adherence to treatment,4 including in Australia5
where most medicines are subsidised by the PBS.
Patients may not necessarily be comfortable
telling a doctor their concerns about prescription
costs, but pharmacists frequently see cost-related
decisions being made at the point of purchase. This
is particularly the case for asthma, since short-acting
reliever inhalers, such as salbutamol, are cheaper
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than inhaled corticosteroids and have a rapid effect.
However, reliance on reliever inhalers, especially
without a preventer, increases the risks of severe
asthma exacerbations.6
Many clinicians are not aware that the average cost
for patients with most low-dose corticosteroid-only
preventers is substantially lower than treatment
with a combination inhaled corticosteroid and
long‑acting beta2 agonist. There are several options
for prescribing low-dose preventers for adults that
give the lowest average monthly out-of-pocket cost
for the patient. Consider the dose, the frequency
of administration and the number of actuations
(single metered doses) in each inhaler (see Table).
When averaged over a year, the cost of a lowdose inhaled corticosteroid can be strikingly low,
as little as 15–30% of the out-of-pocket cost of any
combination inhaler.

Inhaled corticosteroids are very effective –
low dose and affordable cost do not mean
low benefit
For most patients, 80–90% of the benefit of inhaled
corticosteroids is obtained with low doses, if taken
regularly and correctly. For example, in a large
community study, the risk of dying of asthma was
lower for patients who were dispensed four or more
low-dose corticosteroid inhalers per year compared
with those who received none.7 In a large randomised
controlled trial, the risk of serious exacerbations
(emergency department visits, hospitalisations,
death) was also halved and symptoms were
significantly reduced with regular use of budesonide
400 micrograms/day, even in patients with symptoms
as infrequent as once a week or less.8
© 2018 NPS MedicineWise

160
100
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Ciclesonide (pressurised metered-dose inhaler)

Beclometasone (pressurised metered-dose inhaler)

Fluticasone (dry powder inhaler)

$24.16

$39.09

$39.50

$39.50

General

50/5

Fluticasone propionate/formoterol (eformoterol)
(pressurised metered-dose inhaler)
$39.50

$39.50

$39.50

$39.50

$6.40

$6.40

$6.40

$6.40

6
50
100
6
50

•• with formoterol (eformoterol) (dry powder inhaler)
OR

•• with salmeterol (dry powder inhaler)

Beclometasone (pressurised metered‑dose inhaler)

•• with formoterol (eformoterol) (dry powder inhaler)
OR

•• with salmeterol (dry powder inhaler)
$39.50

$33.24

$39.09

$39.50

$33.24

$39.50

$6.40

$6.40

$6.40

$6.40

$6.40

$6.40

60

60

200

60

60

120

60

120

120

120

60

200

120

200

Total
actuations
per script

1 twice daily

1 twice daily

2 once daily
(or 1 twice daily)

1 twice daily

1 twice daily

1 once daily

1 twice daily

2 twice daily

2 once daily
(or 1 twice daily)

2 twice daily

1 twice daily

2 once daily
(or 1 twice daily)

1 once daily

1 once daily

Regimen to achieve
low total inhaled
corticosteroid dose*
(actuations)

1.0

1.0

3.3

1.0

1.0

4.0

1

1

2

1

1.0

3.3

4.0

6.7

Number
of months
supply from
one script

Total $51.23

Total $44.97

Total $49.38

Total $43.12

$39.50

$39.50

$19.75

$39.50

$24.16

$11.73

$9.88

$5.93

General

Total $8.34

Total $8.34

Total $8.00

Total $8.00

$6.40

$6.40

$3.20

$6.40

$6.40

$1.94

$1.60

$0.96

Concession

Maximum cost to patient
per month (30 days)

*	The low total daily inhaled corticosteroid dose is based on the Australian Asthma Handbook table of inhaled corticosteroid doses for adults – www.asthmahandbook.org.au/table/show/22. For each
drug, this column shows how to prescribe a low-dose inhaled corticosteroid regimen with the lowest patient copayment. These regimens are based on the recommended number of actuations and
dosing frequency in the approved product information. The calculations were based on 2018 costs and copayments, available from www.pbs.gov.au.
†	Separate inhalers should only be prescribed if a suitable combination inhaler is not available, and the clinician is certain that the patient will continue to take the inhaled corticosteroid regularly, and
the patient can use the two different inhaler devices correctly.

160

Ciclesonide (pressurised metered-dose inhaler)

Low-dose inhaled corticosteroid and long-acting beta 2 agonist treatment in separate inhalers †

100/50

200/6

Budesonide/formoterol (eformoterol)
(dry powder inhaler)

Fluticasone propionate/salmeterol
(dry powder inhaler)

100/6

Budesonide/formoterol (eformoterol)
(dry powder inhaler)

$6.40

$6.40

$6.40

$6.40

Concession

Maximum price to patient
per script

Low-dose inhaled corticosteroid/long-acting beta 2 agonist combination treatment

400

Formulation
(micrograms
per actuation)

Budesonide (dry powder inhaler)

Low-dose inhaled corticosteroid-only treatment

Drug

Table Minimising the costs of asthma therapy
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Using a preventer inhaler correctly reduces
treatment costs
Patients can save costs by using their inhaler
correctly. If their inhaler technique is incorrect, the
drug is being wasted, as it does not reach the airways.
This is the case for such a high proportion of patients
(up to 80%) that inhaler technique can be assumed
to be incorrect until proven otherwise. Health
professionals need to know the correct technique
for the type of inhaler being prescribed, and watch
the patient using it. Clear step-by-step videos are
available online (www.nationalasthma.org.au/
health-professionals/how-to-videos, www.nps.org.au/
medical-info/consumer-info/inhaler-devices-forrespiratory-medicines).

Book a review visit if treatment has
been started or changed
Patients usually start to feel the benefit from inhaled
corticosteroids quite quickly, within 1–2 weeks, and
they continue to improve for up to 18 months. If
their asthma symptoms are still not controlled after
2–3 months, check adherence and inhaler technique
before considering stepping up treatment to a
combination of a low-dose inhaled corticosteroid and
a long-acting beta2 agonist.
Combining a corticosteroid with a long-acting
beta2 agonist reduces exacerbations on average
by 20%. These can be reduced further if low-dose
budesonide/formoterol (eformoterol) is prescribed
as ‘maintenance and reliever therapy’, that is as both
the patient’s regular maintenance inhaler (usually
twice daily) and as their reliever inhaler (instead of
salbutamol). However, contrary to expectations,
adding a long-acting beta2 agonist has surprisingly

little effect on the use of reliever inhalers.9 After
asthma has been well-controlled for 2–3 months,
treatment can be gradually stepped down to find the
patient’s minimum effective dose.

Shared decision making improves
asthma outcomes
Shared decision making, either when treatment is first
discussed or at a review visit, improves adherence
and asthma outcomes.10 As clinicians, we need to be
aware of the contribution out-of-pocket costs have to
patients’ day-to-day adherence, and to know the cost
implications of what we prescribe. For some patients,
offering a more affordable option may make the
difference between their choosing to take a regular
preventer inhaler, and ‘making do’ with a reliever
alone, with the attendant risk of worse outcomes.
Given the difference in cost, many patients may be
interested in trying an inhaled corticosteroid-only
inhaler first, rather than a combination inhaler, if the
likely benefit and its time course are explained.
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